FGFR inhibition enhances immune checkpoint blockade in preclinical models

◇ RESEARCH

Combining FGFR pathway inhibition with PD-1 blockade reduced T cell exhaustion and promoted antitumor macrophage activity in microsatellite stable colorectal cancer models, with TCGA data showing high FGFR3 expression correlates with worse prognosis. (BMC Cancer)